Key result
Novel SAVR tissue valves linked to ~£408 savings and marginal QALY gains versus mechanical valves.
Why the study?
The study was conducted to conceptualize and evaluate the potential cost-effectiveness and economic drivers of a novel tissue valve versus mechanical heart valves for SAVR in UK patients aged 55-64 and 65+ with AS.
Is a novel tissue valve cost-effective compared to mechanical valves for surgical aortic valve replacement in people aged 55 and older with aortic stenosis?
Is a novel tissue valve cost-effective compared to mechanical valves for surgical aortic valve replacement in people aged 55 and older with aortic stenosis?
A novel tissue valve for surgical aortic valve replacement appears to be a cost-effective alternative to mechanical valves for patients over 55 in the UK.
May support novel tissue valves for UK patients ≥55; leaves open need for randomized confirmation.
OBJECTIVE: Exploratory analysis to conceptualize and evaluate the potential cost-effectiveness and economic drivers of using a novel tissue valve compared with mechanical heart valves for surgical aortic valve replacement (SAVR) in people aged 55-64 and 65+ with aortic stenosis (AS) from a National Health Service (NHS) UK perspective. METHODS: A decision-analytic model was developed using a partitioned survival model. Parameter inputs were obtained from published literature. Deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted to explore the uncertainty around the parameters. RESULTS: The novel tissue valve was potentially associated with higher quality-adjusted life years (QALYs) of 0.01 per person. Potential cost savings were greatest for those aged 55-64 (£408) versus those aged 65+(£53). DSA indicated the results to be most dependent on relative differences in general mortality, procedure costs, and reoperation rates. PSA estimated around 75% of the iterations to be cost-effective at £20,000 per QALY for those aged 55-64, and 57% for those aged 65+. CONCLUSIONS: The exploratory analysis suggests that the novel tissue valve could be a cost-effective intervention for people over the age of 55 with AS who are suitable for SAVR in the UK.
No takes yet. Share an insight, caveat, or question.
Malcolm et al. (2023) studied aortic stenosis. novel tissue valve vs. mechanical heart valves was evaluated on cost-effectiveness (QALYs and cost savings). A novel tissue valve for surgical aortic valve replacement was associated with 0.01 higher QALYs per person and cost savings of £408 (ages 55-64) and £53 (ages 65+) compared to mechanical valves.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: